AES 14

Drug Profile

AES 14

Alternative Names: Aesgen-14; E 6014; L-glutamine suspension - Aesgen; Saforis; Uptake-enhanced L-glutamine suspension

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MGI Pharma
  • Developer Eisai Co Ltd
  • Class Antianaemics; Basic amino acids; Diamino amino acids; Neutral amino acids; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Stomatitis

Most Recent Events

  • 15 May 2012 Discontinued - Phase-III for Stomatitis in USA (PO)
  • 01 Nov 2011 Phase III development is ongoing in US
  • 29 Jan 2008 MGI Pharma has been acquired by Eisai
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top